Zafuleptine

Zafuleptine

SCHEMBL2110004

CC(C)C(CCCCCC(=O)O)NCc1ccc(F)cc1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.48
FOLH1 Q04609 2/20 0.46
TBXA2R P21731 3/20 0.46
MAPK1 P28482 1/20 0.45
PTGER1 P34995 1/20 0.44
PTGFR P43088 1/20 0.44
HPGD P15428 2/20 0.43
LMNA P02545 2/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
S1PR1 P21453 1/20 0.39
S1PR3 Q99500 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11516002 1.00 HTT (0.48) HTTFOLH1TBXA2RMAPK1PTGER1
SCHEMBL11519292 1.00 HTT (0.48) HTTFOLH1TBXA2RMAPK1PTGER1
SCHEMBL11519593 0.99 HTT (0.49) HTTFOLH1TBXA2RMAPK1PTGER1
SCHEMBL11516163 0.89 HPGD (0.43) HTTFOLH1MAPK1HPGDLMNA
SCHEMBL11515011 0.88 DPP7 (0.46) FOLH1HPGDLMNAMEN1KMT2A
SCHEMBL11515245 0.85 LMNA (0.49) HTTFOLH1MAPK1HPGDLMNA
SCHEMBL11518505 0.85 MAPK1 (0.49) HTTFOLH1MAPK1HPGDLMNA
SCHEMBL11516756 0.84 HPGD (0.42) FOLH1MAPK1HPGDLMNAHDAC3
SCHEMBL11515838 0.83 FOLH1 (0.46) HTTFOLH1TBXA2RMAPK1HPGD
SCHEMBL11516594 0.83 HTT (0.45) HTTFOLH1TBXA2RMAPK1PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115739125-A Cobalt boride-loaded sulfur-defect indium zinc sulfide photocatalyst and preparation method and application thereof 湖南工商大学 2023-03-07 CN claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-20040242594-A1 Prodrugs of antidepressants and their use for treating depressions NEUROSEARCH A/S (DK) 2004-12-02 US claimed
EP-1448512-A1 PRODRUGS OF ANTIDEPRESSANTS AND THEIR USE FOR TREATING DEPRESSIONS NeuroSearch A/S (DK) 2004-08-25 EP claimed
WO-2003042162-A1 PRODRUGS OF ANTIDEPRESSANTS AND THEIR USE FOR TREATING DEPRESSIONS NEUROSEARCH A/S (DK) 2003-05-22 WO claimed
US-4154851-A ANTIDEPRESSANTS, ANTIAGRESSIVE AGENTS SCIENCE UNION ET CIE, SOCIETE FRANCAISE DE RECHERCHE MEDICALE (FR) 1979-05-15 US claimed
WO-2025129358-A1 STABLE FILM FORMULATIONS FOR HIGH LOADING OF LOW MELTING POINT ACTIVES INTELGENX CORP. (CA) 2025-06-26 WO disclosed
US-12168718-B2 Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) 2024-12-17 US disclosed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
US-4154851-A ANTIDEPRESSANTS, ANTIAGRESSIVE AGENTS SCIENCE UNION ET CIE, SOCIETE FRANCAISE DE RECHERCHE MEDICALE (FR) 1979-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12168718-B2 Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel HSPB1, HSPA1B, BOLA2; BOLA2B HTT 4363/4885FOLH1 4883/4885TBXA2R 481/4885
US-20040242594-A1 Prodrugs of antidepressants and their use for treating depressions TPH1, SLC6A4, TPH2 HTT 1313/4885FOLH1 307/4885TBXA2R 1930/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 HTT 2183/4885FOLH1 168/4885TBXA2R 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.